|Bid||3.0500 x 1300|
|Ask||3.3900 x 1200|
|Day's Range||3.0600 - 3.2500|
|52 Week Range||3.0600 - 35.7750|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||35.67|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.00|
Subscribe to Yahoo Finance Plus to view Fair Value for ICVX
Insiders who acquired US$300k worth of Icosavax, Inc.'s ( NASDAQ:ICVX ) stock at an average price of US$7.10 in the...
Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of -3.64% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
– Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) - – Icosavax plans to file an IND and initiate a Phase 1 trial for IVX-A12, a combination bivalent RSV + human metapneumovirus (hMPV) VLP candidate, in 2H 2022 - – IVX-411 (COVID-19) drug product investigation confirmed molecule-specific instability of antigen component and no evidence of read-through to other Icosavax programs - - Cash and cash equivalents, restric